News

Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

MMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for…

12 months ago

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of…

12 months ago

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in…

12 months ago

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of studyBOSTON and…

12 months ago

NKGen Announces Poster Presentation at the 2023 Alzheimer’s Association International Conference

SANTA ANA, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the…

12 months ago

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers…

12 months ago

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Four poster presentations provided detailed and new data on the achievement of primary and secondary endpoints, improvements in investigator-rated outcomes,…

12 months ago

MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer

CARMEL, Ind., July 10, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™…

12 months ago

Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement…

12 months ago